iBio (IBIO): Our Last Line of Defense Against Ebola?

On October 9, U-T San Diego reported that Mapp Biopharmaceutical enlisted a company to help produce the Ebola drug cocktail, ZMapp.
And widespread speculation was that iBio (IBIO) would be identified as Mapp’s partner.
As a result, iBio’s shares spiked more than 66.6% on Columbus Day.
The Delaware-based biotech company closed the trading day at $2.45, an increase of more than $0.98 from Friday’s closing price of $1.47.
More than 49 million shares changed hands, compared to the three-month average of just over 600,000.
This proves without a doubt that hysteria about Ebola has reached Wall Street.

Don’t Get Caught in This Terror Trap

I’m sure you’ve heard by now that a nurse in Dallas was diagnosed with the Ebola virus after having extensive contact with a patient who later died of the deadly virus.
The news significantly deepened concerns about an Ebola outbreak thas have plagued the United States since late September.
As you can see from the chart below, iBio shares have blasted higher on both Friday and Monday.

Now, you might be asking what role in the fight against Ebola iBio plays…(more)
Please share this article